BidaskClub cut shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a buy rating to a hold rating in a research note published on Saturday morning.
A number of other equities research analysts also recently issued reports on the company. B. Riley upped their price objective on AMAG Pharmaceuticals from $16.00 to $23.00 and gave the company a neutral rating in a research report on Wednesday, March 14th. Jefferies Group downgraded AMAG Pharmaceuticals from a buy rating to a hold rating and decreased their price objective for the company from $21.00 to $20.00 in a research report on Monday, March 5th. Piper Jaffray restated a hold rating and set a $20.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, March 1st. Morgan Stanley upped their price objective on AMAG Pharmaceuticals from $22.00 to $24.00 and gave the company an overweight rating in a research report on Wednesday, February 28th. Finally, ValuEngine upgraded AMAG Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, February 28th. Twelve equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $23.91.
Shares of AMAG stock opened at $19.70 on Friday. AMAG Pharmaceuticals has a 1 year low of $11.93 and a 1 year high of $24.85. The company has a current ratio of 1.74, a quick ratio of 1.60 and a debt-to-equity ratio of 0.93. The company has a market cap of $659.62, a price-to-earnings ratio of -3.45 and a beta of 0.09.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Balter Liquid Alternatives LLC bought a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at approximately $120,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at approximately $161,000. Teacher Retirement System of Texas bought a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at approximately $162,000. Two Sigma Securities LLC bought a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at approximately $187,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of AMAG Pharmaceuticals during the third quarter valued at approximately $197,000.
TRADEMARK VIOLATION NOTICE: “AMAG Pharmaceuticals (AMAG) Downgraded by BidaskClub” was originally reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2018/04/24/amag-pharmaceuticals-amag-downgraded-by-bidaskclub.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.